Geoff Hurst lends support to prostate cancer campaign A new campaign highlighting the inequality of treatment in men with prostate cancer has been launched with the help of England football hero Geoff Hurst.It aims to raise awareness of the fact that 7 out of 10 men with advanced prostate...
Geoff Hurst lends support to prostate cancer campaign A new campaign highlighting the inequality of treatment in men with prostate cancer has been launched with the help of England football hero Geoff Hurst.It aims to raise awareness of the fact that 7 out of 10 men with advanced prostate...
Adding Taxane to Anthracycline-Based Therapy Does Not Improve Outcomes SAN ANTONIO-Giving a taxane following standard anthracycline-based chemotherapy for early breast cancer will not improve outcomes, suggest results of a 104-center, British study presented at the San Antonio Breast Cancer Symposium.There...
Two New Herceptin-Containing Regimens Approved The FDA has approved two new regimens containing trastuzumab (Herceptin) for the adjuvant treatment of HER2 node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer.The first regimen, known as TCH ...
Celsion Corporation: Tumor Targeting Docetaxel Abstract Selected for Presentation at the 11th Liposome Researc Tumor Targeting Docetaxel Abstract Selected for Presentation at the 11th Liposome Research Days Conference (NewsRx.com) -- CELSION CORPORATION (NASDAQ: CLN) announced that its docetaxel thermosensitive liposome preclinical study results will...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor Study seeks to determine if presence of certain gene impacts patient outcome MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.-- (BUSINESS WIRE) -- GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the initiation of a Phase 2 study evaluating satraplatin in combination with the steroid,...
GPC Biotech Initiates Mid-Stage Trial Of Satraplatin In Prostate Cancer Patients (RTTNews) - GPC Biotech AG (GPCB: News, Chart, Quote ) said Tuesday that it has initiated a mid-stage trial to assess satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer or...
GPC starts Phase II study on satraplatin cancer drug with prednisone steroid MARTINSRIED, Germany (Thomson Financial) - GPC Biotech AG.said it started a Phase II study in the United States, testing its experimental drug satraplatin in combination with the steroid prednisone on prostate cancer patients that could...
GPC starts Phase II study on satraplatin cancer drug with prednisone steroid MARTINSRIED, Germany (Thomson Financial) - GPC Biotech AG.said it started a Phase II study in the United States, testing its experimental drug satraplatin in combination with the steroid prednisone on prostate cancer patients that could...
GPC starts Phase II study on satraplatin cancer drug with prednisone steroid MARTINSRIED, Germany (Thomson Financial) - GPC Biotech AG.said it started a Phase II study in the United States, testing its experimental drug satraplatin in combination with the steroid prednisone on prostate cancer patients that could...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor GPC Biotech AG (Frankfurt Stock Exchange: GPC,GPCB) today announced the initiation of a Phase 2 study evaluating satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer (HRPC)...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor Study seeks to determine if presence of certain gene impacts patient outcome MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.-- (Business Wire) GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the initiation...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the initiation of a Phase 2 study evaluating satraplatin in combination with the steroid,...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the initiation of a Phase 2 study evaluating satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the initiation of a Phase 2 study evaluating satraplatin in combination with the steroid,...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor Study seeks to determine if presence of certain gene impacts patient outcome MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the initiation of a...
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hor (GMT+1) Study seeks to determine if presence of certain gene impacts patient outcome Martinsried/Munich (Germany) and Princeton, N.J., June 24, 2008 - (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the initiation of a Phase 2...
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refr - GPC Biotech AG announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, an oral platinum compound.The patent is entitled, 'Satraplatin for treating resistant or refractory tumors' and covers certain uses of...
GPC Biotech gets EU patent for satraplatin GPC Biotech AG announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum compound.The patent is entitled, 'Satraplatin for treating resistant or refractory tumours' and covers certain...
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refr MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.-- (BUSINESS WIRE) -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral...
New Roche data to be presented at ASCO offers further hope for cancer patients Basel, 15th May 2008 - Patients with breast or colorectal cancer, two of the world's most common cancers, can expect further treatment advances with Avastin (bevacizumab) and Herceptin (trastuzumab) following new data that is being presented...
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refr MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.- (Business Wire) GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral...
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refr GPC Biotech AG (Frankfurt Stock Exchange: GPC;GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum compound.The patent is entitled, "Satraplatin for treating resistant or...
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refr MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral...
